So 4 patients out of 12 that started the phase 1 study have shown stable or slight improvement.
The question is, is a 33% good enough, and what about the other 6 that's not accounted for, it appears they have the disease progressing
Ann: OLE Study update reveals impressive Survival Data, page-211
Add NUZ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
0.005(3.03%) |
Mkt cap ! $83.62M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 17.5¢ | 16.5¢ | $34.56K | 202.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 9955 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 133138 | 3 |
View Market Depth
| Last trade - 15.39pm 27/12/2024 (20 minute delay) ? |
| NUZ (ASX) Chart |
